This roundtable brings together some of RGA’s top biometric experts to examine new research on GLP‑1 therapies. The discussion explores long-term mortality trends, real‑world constraints, and what insurers should be watching next across global markets. Spend 23 minutes with our experts to gain a sharper view of GLP‑1 risk.
Key takeaways
- GLP-1 therapies have the potential to materially influence future mortality trends, with impacts varying by market, age, and uptake.
- Real world constraints – cost, adherence, and side effects – will shape outcomes, creating material differences between trial data and lived experience.
- Mortality impacts are expected to be stronger than morbidity effects, with important implications for pricing, underwriting, and product strategy.
- Insured populations may see smaller benefits than the general population, reflecting differences in baseline health and socioeconomic profile.
- As indications expand beyond obesity and diabetes, insurers will need flexible frameworks to manage uncertainty and emerging risk.
